Published Date: 29 Mar 2024
For patients with enzyme deficiencies, treatment can be fatal; NCCN does not recommend preemptive testing.
Read Full NewsTake 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 6, 2026.
A new comparison study of patients with autoimmune diseases reported high rates of anxiety and depression, with notable differences in when psychiatric symptoms emerged relative to disease onset.
A real-world study showed that cladribine tablets were associated with greater treatment persistence and lower health care costs in patients with multiple sclerosis compared with other common therapies.
The single-arm CLAD-MAPET study is evaluating whether cladribine tablets reduce microglial activation, captured by [F-18]PBR06-PET, in patients with MS experiencing progression without relapse or MRI activity on anti-CD20 therapy.
Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD
The HCPFive: Top News for Healthcare Providers from the Week of 02/01
HCPLive 5 Stories in Under 5: Week of 02/01
1.
FDA Expands Durvalumab Label to Operable Lung Cancer
2.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
3.
Top Options Are Discovered Through Direct Comparison of 25 Migraine Drugs.
4.
Six breast texture patterns linked to higher risk of invasive cancer
5.
Cancer Patients Are Receiving More and More Stupid Immunotherapy.
1.
Tertiary Lymphoid Structures: Pivotal Players in Cancer Prognosis and Therapeutic Response
2.
Liquid Biopsy: Revolutionizing Precision Oncology in Hematological Malignancies
3.
Subchorionic Hematoma: Causes, Symptoms, and Treatment
4.
Immuno-Oncology in Daily Practice: Transforming Cancer Care One Patient at a Time
5.
From Birthmarks to Tumors: The Science Behind Infantile Hemangioma
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
2.
Current Scenario of Cancer- Q&A Session to Close the Gap
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation